The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Year: 2020
Type: article
Abstract: Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.
Institutions: University of California, San Francisco, Beth Israel Deaconess Medical Center, Sarah Cannon, Johns Hopkins University, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Icahn School of Medicine at Mount Sinai, Abramson Cancer Center, University of Pennsylvania, Fred Hutch Cancer Center, City Of Hope National Medical Center, City of Hope, Mayo Clinic, The University of Texas MD Anderson Cancer Center, Harvard University, Dana-Farber Cancer Institute, Emory University, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Winship Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,490
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Sanofi, Gilead Sciences, Teva Pharmaceutical Industries, Spectrum Pharmaceuticals, Celgene, BioClinica, Society for Immunotherapy of Cancer, Prothena, Quest Diagnostics, bluebird bio, Adaptive Biotechnologies, Glenmark Pharmaceuticals, Servier, National Institutes of Health, Genentech, Kite Pharma, Pharmacyclics, Juno Therapeutics, National Cancer Institute, National Center for Advancing Translational Sciences
OpenAlex ID: W3041796883